Washington, D.C. (March 13, 2021) - UsAgainstAlzheimer’s issued the following statement on the release by Eli Lilly of full results of its phase 2 clinical trials on donanemab at the International Conference on Alzheimer's & Parkinson Diseases 2021 and in an article in the New England Journal of Medicine. The results expand on previously reported top-line data that found donanemab showed significant slowing of decline in patients with early symptomatic Alzheimer's disease.

“Today, we know more about Alzheimer’s than we did yesterday, and clinical trials for this drug treatment show that it could slow decline by a third. That’s progress. That’s hope. It’s getting us closer to a world where nobody is lost to Alzheimer’s.

“This is the latest promising sign of the progress and potential of innovative treatments for people living with Alzheimer’s, their caregivers and families. The results found that donanemab slowed cognitive and functional decline in patients with early symptomatic Alzheimer's disease and also slowed the accumulation of tau across key brain regions in patients. 

“After years of disappointment about potential drug treatments, this is yet another optimistic step forward on a path towards effective treatments, prevention and ultimately a cure for Alzheimer’s. The FDA is currently reviewing another disease-modifying therapy and a separate drug for delusion-related hallucinations and delusions.

“Effective treatments and a cure would bring relief to the millions of Americans with Alzheimer’s, their caregivers, and loved ones – particularly to communities of color who are disproportionately impacted.

“We look forward to the results of the next set of clinical trials for donanemab.

“UsAgainstAlzheimer’s offers its special thanks to the patients who have participated in donanemab clinical trials. We also thank Eli Lilly & Co. for its perseverance in developing donanemab as a treatment for Alzheimer’s disease and its work to better detect and ultimately find a way to stop this insidious disease.”

###